SCHEMBL2265830

SCHEMBL2265830

NC(Cc1ccc(N2CCNCC2)cc1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.53
PTGS1 P23219 3/20 0.51
ALPI P09923 1/20 0.51
PKM P14618 1/20 0.51
XIAP P98170 1/20 0.51
ALDH1A1 P00352 4/20 0.50
USP2 O75604 2/20 0.50
HSD17B10 Q99714 2/20 0.50
TSHR P16473 1/20 0.50
ADRB1 P08588 3/20 0.46
HTR3E A5X5Y0 2/20 0.46
HTR3B O95264 2/20 0.46
HTR3A P46098 2/20 0.46
HTR3D Q70Z44 2/20 0.46
HTR3C Q8WXA8 2/20 0.46
SIGMAR1 Q99720 2/20 0.46
TYR P14679 5/20 0.46
TPH1 P17752 1/20 0.46
GRB2 P62993 1/20 0.46
KDM4E B2RXH2 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31329363 1.00 SLC7A5 (0.53) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL18280216 0.89 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL16861052 0.89 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL2779539 0.86 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL2779534 0.86 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL6776419 0.85 SLC7A5 (0.56) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL6776426 0.85 SLC7A5 (0.56) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL30118367 0.84 GRIA2 (0.56) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL8953360 0.84 ALDH1A1 (0.51) ALDH1A1USP2HSD17B10TSHRADRB1
SCHEMBL5024981 0.84 SLC7A5 (0.54) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116923-A1 CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS MERCK SHARP & DOHME LLC (US) 2026-04-30 US disclosed
US-8445440-B2 Dimeric IAP inhibitors NOVARTIS AG (CH) 2013-05-21 US disclosed
EP-2539333-A1 DIMERIC IAP INHIBITORS Novartis AG (CH) 2013-01-02 EP disclosed
WO-2011104266-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-09-01 WO disclosed
US-20110206690-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116923-A1 CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS IL1A, IL1B, IL1RN SLC7A5 3532/4885PTGS1 217/4885ALPI 2772/4885
US-20110206690-A1 DIMERIC IAP INHIBITORS XIAP, BIRC5, BIRC2 SLC7A5 3081/4885PTGS1 3021/4885ALPI 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.